Eva L. Hansson

BioPharmaceuticals R&D, AstraZeneca
Goeteborg, O 43183, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

TRPV4: A Promising Therapeutic Target Ion Channel─Discovery of Ultrapotent Selective Antagonists.

TRPV4: A Promising Therapeutic Target Ion Channel─Discovery of Ultrapotent Selective Antagonists.

Journal: Journal of medicinal chemistry

Published: July 11, 2026

Mineralocorticoid Receptor Antagonists With an Acylurea as a Key Polar Interaction Motif.

Mineralocorticoid Receptor Antagonists With an Acylurea as a Key Polar Interaction Motif.

Journal: ChemMedChem

Published: November 19, 2025

RORγt inverse agonists demonstrating a margin between inhibition of IL-17A and thymocyte apoptosis.

RORγt inverse agonists demonstrating a margin between inhibition of IL-17A and thymocyte apoptosis.

Journal: PloS one

Published: January 23, 2024

AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2.

AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2.

Journal: Journal of medicinal chemistry

Published: August 31, 2021

Fragment-Based Discovery of Novel Allosteric MEK1 Binders.

Fragment-Based Discovery of Novel Allosteric MEK1 Binders.

Journal: ACS medicinal chemistry letters

Published: October 20, 2020

Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2.

Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2.

Journal: ACS medicinal chemistry letters

Published: April 05, 2019

Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection.

Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection.

Journal: Journal of medicinal chemistry

Published: January 01, 2019

Potent and Orally Bioavailable Inverse Agonists of RORγt Resulting from Structure-Based Design.

Potent and Orally Bioavailable Inverse Agonists of RORγt Resulting from Structure-Based Design.

Journal: Journal of medicinal chemistry

Published: August 11, 2018

Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity.

Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity.

Journal: ChemMedChem

Published: October 19, 2016

Benzoxazepines Achieve Potent Suppression of IL-17 Release in Human T-Helper 17 (TH 17) Cells through an Induced-Fit Binding Mode to the Nuclear Receptor RORγ.

Benzoxazepines Achieve Potent Suppression of IL-17 Release in Human T-Helper 17 (TH 17) Cells through an Induced-Fit Binding Mode to the Nuclear Receptor RORγ.

Journal: ChemMedChem

Published: September 21, 2015

Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods.

Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods.

Journal: Journal of computer-aided molecular design

Published: July 08, 2015

Assessing HTS performance using BioAssay Ontology: screening and analysis of a bacterial phospho-N-acetylmuramoyl-pentapeptide translocase campaign.

Assessing HTS performance using BioAssay Ontology: screening and analysis of a bacterial phospho-N-acetylmuramoyl-pentapeptide translocase campaign.

Journal: Assay and drug development technologies

Published: November 22, 2014

Showing 1-12 of 12

Last Updated: 09/26/2026